Growth factors and chronic wound healing: past, present, and future.
Growth factors and chronic wound healing: past, present, and future.
复制标题
DOI：
10.1097/00129334-200401000-00012
复制
发表时间：
2004-01-01
影响因子：
2.4
通讯作者：
Goldman, Robert
中科院分区：
文献类型：
--
作者：
Goldman, Robert
生长物质（细胞因子和生长因子）是影响正常伤口愈合过程的可溶性信号蛋白。细胞因子控制清除细胞和细胞外基质碎片的炎症阶段。伤口修复受生长因子（血小板衍生生长因子[PDGF]、角质形成细胞生长因子和转化生长因子β）控制。内源性生长因子通过真皮-表皮界面传递信息。PDGF对伤口愈合的大多数阶段都很重要。Becaplermin（PDGF-BB）是美国食品和药物管理局批准的唯一生长因子，需要每天应用于神经性伤口愈合。基因疗法正在开发中，用于更有效的生长因子递送;单次应用将诱导组成性生长因子表达数周。基于引人注目的临床前动物研究，计划在PDGF基因构建体上进行的1期临床试验似乎很有希望。
Growth substances (cytokines and growth factors) are soluble signaling proteins affecting the process of normal wound healing. Cytokines govern the inflammatory phase that clears cellular and extracellular matrix debris. Wound repair is controlled by growth factors (platelet-derived growth factor [PDGF], keratinocyte growth factor, and transforming growth factor beta). Endogenous growth factors communicate across the dermal-epidermal interface. PDGF is important for most phases of wound healing. Becaplermin (PDGF-BB), the only growth factor approved by the Food and Drug Administration, requires daily application for neuropathic wound healing. Gene therapy is under development for more efficient growth factor delivery; a single application will induce constitutive growth factor expression for weeks. Based on dramatic preclinical animal studies, a phase 1 clinical trial planned on a PDGF genetic construct appears promising.